Cargando…

Effectiveness and safety of a biosimilar-to-biosimilar switch of the TNF inhibitor etanercept in patients with chronic inflammatory rheumatic diseases

BACKGROUND: Biosimilar disease-modifying anti-rheumatic drugs (bsDMARDs) has created a financial incentive to encourage switching to cheaper products. OBJECTIVES: We aim to study the effectiveness and safety of a non-medical bsDMARD-to-bsDMARD switch from originator etanercept (ETN) to bsDMARD ETN (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kiltz, Uta, Tsiami, Styliani, Baraliakos, Xenofon, Andreica, Ioana, Kiefer, David, Braun, Jürgen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424877/ https://www.ncbi.nlm.nih.gov/pubmed/36051634 http://dx.doi.org/10.1177/1759720X221119593

Ejemplares similares

Treatment with adalimumab in patients with chronic inflammatory rheumatic diseases: a study of treatment trajectories on a patient level in routine care
por: Redeker, Imke, et al.
Publicado: (2023)

Are patients with rheumatic diseases on immunosuppressive therapies protected against preventable infections? A cross-sectional cohort study
por: Kiltz, Uta, et al.
Publicado: (2021)

SARS-CoV-2 vaccination willingness and predictors in patients with chronic inflammatory rheumatic diseases (CIRD) and without CIRD
por: Roman, Iulia, et al.
Publicado: (2022)

Facilitators and barriers for vaccination in patients with inflammatory rheumatic musculoskeletal diseases: a prospective cohort study
por: Andreica, Ioana, et al.
Publicado: (2023)

Etanercept biosimilars
por: Azevedo, Valderilio F., et al.
Publicado: (2014)

Observational study of inflammatory arthritis treatment by etanercept originator switched to an etanercept biosimilar
por: Felis-Giemza, Anna, et al.
Publicado: (2019)

Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis
por: Ditto, Maria Chiara, et al.
Publicado: (2020)

GP2015: An Etanercept Biosimilar
por: Deeks, Emma D.
Publicado: (2017)

Focus on biosimilar etanercept – bioequivalence and interchangeability
por: Cantini, Fabrizio, et al.
Publicado: (2018)

Correction to: GP2015: An Etanercept Biosimilar
por: Deeks, Emma D.
Publicado: (2018)

Facilitators and barriers of vaccine uptake in patients with autoimune inflammatory rheumatic disease: a scoping review
por: Neusser, Silke, et al.
Publicado: (2022)

Wie gut sind Patienten mit entzündlich rheumatischen Erkrankungen gegen Masern geschützt?
por: Kiltz, U., et al.
Publicado: (2020)

Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry
por: Nabi, Hafsah, et al.
Publicado: (2022)

Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review
por: Ebbers, Hans C., et al.
Publicado: (2019)

Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination
por: Andreica, Ioana, et al.
Publicado: (2022)

The Role of Biosimilars in Uveitis: Long-Term Real-World Outcomes of the Switch From Original to Biosimilar TNF-Alpha Inhibitors
por: Fabiani, Claudia, et al.
Publicado: (2019)

Incidence of and Reasons and Determinants Associated with Retransitioning from Biosimilar Etanercept to Originator Etanercept
por: Meijboom, Rosanne W., et al.
Publicado: (2021)

Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis
por: Chadwick, Laura, et al.
Publicado: (2018)

Physicochemical Characterization of Altebrel™, a Proposed Etanercept Biosimilar
por: Fazel, Ramin, et al.
Publicado: (2019)

Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
por: Mysler, Eduardo, et al.
Publicado: (2021)

Management of Axial Spondyloarthritis – Insights into Upadacitinib
por: Braun, Jürgen, et al.
Publicado: (2022)

Biosimilars: To switch or not to switch – that is the question
por: Szekanecz, Zoltán
Publicado: (2020)

Safety and Effectiveness of Etanercept Biosimilar SB4 for Rheumatic Diseases in South Korea: Real-World Post-marketing Surveillance Data
por: Yoo, Wan-Hee, et al.
Publicado: (2022)

Factors for starting biosimilar TNF inhibitors in patients with rheumatic diseases in the real world
por: Sung, Yoon-Kyoung, et al.
Publicado: (2020)

Pearls and Pitfalls in Diagnosing Non-Radiographic Axial Spondyloarthritis
por: Tsiami, Styliani, et al.
Publicado: (2022)

Secukinumab in axial spondyloarthritis: a narrative review of clinical evidence
por: Braun, Jürgen, et al.
Publicado: (2021)

Do patients with ankylosing spondylitis adapt to their disease? Evidence from a ‘then-test’ in patients treated with TNF inhibitors
por: Essers, Ivette, et al.
Publicado: (2015)

High prevalence of chondrocalcinosis and frequent comorbidity with calcium pyrophosphate deposition disease in patients with seronegative rheumatoid arthritis
por: Krekeler, Martin, et al.
Publicado: (2022)

Serum granulocyte-macrophage colony-stimulating factor (GM-CSF) is increased in patients with active radiographic axial spondyloarthritis and persists despite anti-TNF treatment
por: Papagoras, Charalampos, et al.
Publicado: (2022)

Safety of switching between rituximab biosimilars in onco-hematology
por: Urru, Silvana A. M., et al.
Publicado: (2021)

Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn’s Disease: A Prospective Study
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2021)

New developments in ankylosing spondylitis—status in 2021
por: Klavdianou, Kalliopi, et al.
Publicado: (2021)

Erratum to: New developments in Ankylosing spondylitis – Status in 2021
por: Klavdianou, Kalliopi, et al.
Publicado: (2022)

Biosimilar switching – current state of knowledge
por: Wiland, Piotr, et al.
Publicado: (2018)

New Alternatives for Autoimmune Disease Treatments: Physicochemical and Clinical Comparability of Biosimilar Etanercept
por: Miranda-Hernández, Mariana P., et al.
Publicado: (2016)

Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept
por: Cho, Ick Hyun, et al.
Publicado: (2016)

Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany
por: Moorkens, Evelien, et al.
Publicado: (2020)

Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars
por: Ebbers, Hans C., et al.
Publicado: (2020)

Efficacy and Safety of Etanercept Biosimilars Compared With the Originator for Treatment of Juvenile Arthritis: A Prospective Observational Study
por: Thiele, Franz, et al.
Publicado: (2021)

Effectiveness and Safety of Switching from Innovator Infliximab to Biosimilar CT-P13 in Inflammatory Rheumatic Diseases: A Real-World Case Study
por: Vergara-Dangond, Cristina, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_3hmejiuc7tm6e9meccf74e6t74